$AGX

Watson David Hibbert sold $7.8M of AGX

Watson David Hibbert (PRESIDENT AND CEO) sold 11,873 shares of ARGAN INC (AGX) at an average of $660.11 ($651.22–$707.35, $7.84M total) across 2 trades over 2026-06-15 to 2026-06-16.

Original reporting
SEC EDGAR · Watson David Hibbert
Published Jun 16, 2026, 8:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 16, 2026, 8:35 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$AGX
Bearish
medium confidence
Mentioned
$AGX
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$AGXBearishLow
01

Why it matters

A CEO open-market sale of $7.84M can influence short-term sentiment, especially because no 10b5-1 plan is indicated, but it does not provide new information about earnings, guidance, contracts, or operations.

02

Market read

Traders may reassess near-term sentiment and positioning in AGX following the CEO’s disclosed selling activity.

03

What to watch

The filing does not state the reason for the sale; also, the absence of a stated 10b5-1 plan may be less informative than investors assume without additional context.

Relevance 6/10Novelty 8/10Timing: Filed 2026-06-16; sale executed 2026-06-15 to 2026-06-16.

Background

The article is an SEC Form 4 insider transaction disclosure for ARGAN Inc (AGX).

Company-level read

Ticker impact

$AGXBearishMedium confidence
Context

SEC Form 4 shows AGX CEO Watson David Hibbert sold $7.84M of AGX shares in two open-market trades (6/15–6/16).

Expected impact

Likely modest negative bias for AGX shares around the filing/next sessions; magnitude uncertain because the sale is not tied to a disclosed catalyst.

Evidence & confidence

The article discloses a large CEO open-market sale ($7.84M) with no 10b5-1 plan stated, which can increase investor concern, though Form 4 sales are often routine and lack direct operational implications.

Market effects

Limited sector read-through; this is company-specific insider activity rather than an industry catalyst.

No clear regional spillover indicated by the filing details.

Minimal global relevance; disclosure is confined to AGX insider transactions.

Counterpoint

The sale could be for diversification/tax/financing needs and does not necessarily reflect a bearish view of AGX fundamentals.

Key entities

  • ARGAN INC

    Company whose shares were sold by its CEO in the disclosed Form 4 transactions.

  • Watson David Hibbert

    ARGAN Inc President and CEO who sold shares in two open-market trades.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$AGXMedAI 8/10

Argan’s (AGX) Power Boom Comes With A Margin Catch

Argan (AGX) reported record Q2 revenue of $384.0M (+61.5% YoY) and net income of $53.3M, driven by its Power segment. Gross margin slipped to 19.3%, and backlog decreased to $2.5B. The company is debt-free with $1.03B in cash, returning $51.7M to shareholders. Management expects new projects but faces regulatory challenges and margin compression.

$AGXHigh

Why Argan Stock Swooned by Almost 8% Today

Argan (AGX) stock fell 8% after Piper Sandler analyst Dimple Gosai initiated coverage with an underweight rating and a $273 price target, citing capacity limits and a potential peak in project awards.

$AGXMed

Argan (AGX) Q2 2027 Earnings Call Transcript

Argan (AGX) reported Q2 2027 revenue of $384.0M, up 61.5%, with net income of $53.3M ($3.76 per diluted share). Power segment revenue grew 53% YoY to $301M, while Industrial segment revenue rose 111% to $76M. Consolidated backlog decreased to $2.5B. The company plans to complete a new fabrication facility in North Carolina by Q3 2027.

$AGXMedAI 8/10

Is Argan Worth Buying as Growth Surges but Valuation Stays Elevated?

Argan, Inc. (AGX) reported 56.5% revenue growth to $674.9M and adjusted EBITDA growth to $126.5M in H1 2027. The company expects 45.4% sales and 38% earnings growth for fiscal 2027, with a $2.5B backlog. However, margins have declined, and valuation remains high. Management highlights multi-year visibility but warns of execution risks.